ea0063oc2.4 | Diabetes 1 | ECE2019
Dimitriadis Georgios K
, Nasiri-Ansari Narjes
, Agrogannis Georgios
, Nikiteas Nikolaos
, Kostakis Ioannis D
, Kaltsas Gregory
, Papavassiliou Athanasios G
, Kassi Eva
, Randeva Harpal S
Background: Sodium glucose co-transporter 2 inhibitors reduce the incidence of cardiovascular events in patients with type 2 diabetes mellitus based on the results of recent cardiovascular outcome studies. Herein, we investigated the effects of long-term treatment with empagliflozin on biochemical and immunohistochemical markers related to atherosclerosis development in apolipoprotein E knockout [Apo-E(−/−)] mice.Methods: At the ag...